{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:44:41Z","timestamp":1746218681259},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00404-008-0592-9","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T09:19:24Z","timestamp":1202894364000},"page":"457-462","source":"Crossref","is-referenced-by-count":11,"title":["Oxaliplatin\/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma"],"prefix":"10.1007","volume":"278","author":[{"given":"Daniela D.","family":"Rosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max S.","family":"Mano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Selleslags","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Lebrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine J.","family":"Piccart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"D\u2019Hondt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"key":"592_CR1","unstructured":"US Census Bureau, International Data Base, 2004. http:\/\/www.cureresearch.com\/o\/ovarian_cancer\/stats-country.htm"},{"issue":"3","key":"592_CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1200\/JCO.1991.9.3.389","volume":"9","author":"M Markman","year":"1991","unstructured":"Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9(3):389\u2013393","journal-title":"J Clin Oncol"},{"issue":"12","key":"592_CR3","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","volume":"11","author":"EL Trimble","year":"1993","unstructured":"Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS et al (1993) Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11(12):2405\u20132410","journal-title":"J Clin Oncol"},{"issue":"12","key":"592_CR4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1023\/A:1013558501425","volume":"12","author":"T Meyer","year":"2001","unstructured":"Meyer T, Nelstrop AE, Mahmoudi M, Rustin GJ (2001) Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol 12(12):1705\u20131709","journal-title":"Ann Oncol"},{"issue":"5","key":"592_CR5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","volume":"16","author":"AJ Gonzalez-Martin","year":"2005","unstructured":"Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study. Ann Oncol 16(5):749\u2013755","journal-title":"Ann Oncol"},{"issue":"10","key":"592_CR6","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9(10):1053\u20131071","journal-title":"Ann Oncol"},{"issue":"24","key":"592_CR7","first-page":"5970","volume":"53","author":"L Pendyala","year":"1993","unstructured":"Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53(24):5970\u20135976","journal-title":"Cancer Res"},{"issue":"1","key":"592_CR8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2004.06.029","volume":"95","author":"D Pectasides","year":"2004","unstructured":"Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M et al (2004) Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol Oncol 95(1):165\u2013172","journal-title":"Gynecol Oncol"},{"issue":"16","key":"592_CR9","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u20132947","journal-title":"J Clin Oncol"},{"key":"592_CR10","unstructured":"Common Terminology Criteria for Adverse Events, Version 3.0, Revised 10 June, 2003. National Cancer Institute. http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf"},{"issue":"3","key":"592_CR11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"592_CR12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ et al (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14(5):1545\u20131551","journal-title":"J Clin Oncol"},{"issue":"16","key":"592_CR13","first-page":"3579","volume":"58","author":"A Vaisman","year":"1998","unstructured":"Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC et al (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58(16):3579\u20133585","journal-title":"Cancer Res"},{"issue":"1","key":"592_CR14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9\u201323","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"592_CR15","first-page":"4881","volume":"56","author":"D Fink","year":"1996","unstructured":"Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A et al (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56(21):4881\u20134886","journal-title":"Cancer Res"},{"issue":"2","key":"592_CR16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ygyno.2006.03.017","volume":"103","author":"CB Steer","year":"2006","unstructured":"Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH et al (2006) Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study. Gynecol Oncol 103(2):439\u2013445","journal-title":"Gynecol Oncol"},{"key":"592_CR17","doi-asserted-by":"crossref","unstructured":"Tournigand CCE, Maindrault Goebel F et al (2005) Docetaxel (D) and oxaliplatin (DOCELOX) in advanced ovarian cancer (AOC): preliminary safety results of a phase I\u2013II (meeting abstracts). J Clin Oncol 23. Abstract 5104","DOI":"10.1200\/jco.2005.23.16_suppl.5104"},{"key":"592_CR18","doi-asserted-by":"crossref","unstructured":"Gorbounova VTS, Besova N (2005) Phase II trial of oxaliplatin (OXA) and topotecan (TOP) as a first line treatment for the patients (pts) with advanced ovarian cancer (AOC): preliminary results of a pilot study (meeting abstracts). J Clin Oncol 23. Abstract 5116","DOI":"10.1200\/jco.2005.23.16_suppl.5116"},{"key":"592_CR19","unstructured":"Deplanque GGA, Fabbro M et al (2004) Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) as first-line chemotherapy for patients (pts) with advanced ovarian cancer (AOC): preliminary results (meeting abstracts). J Clin Oncol 22. Abstract 5075"},{"issue":"10","key":"592_CR20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1023\/A:1012556627852","volume":"12","author":"JL Misset","year":"2001","unstructured":"Misset JL, Vennin P, Chollet PH, Pouillart P, Laplaige PH, Frobert JL et al (2001) Multicenter phase II\u2013III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol 12(10):1411\u20131415","journal-title":"Ann Oncol"},{"issue":"15","key":"592_CR21","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2003.03.077","volume":"21","author":"PM Fracasso","year":"2003","unstructured":"Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS (2003) Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J Clin Oncol 21(15):2856\u20132859","journal-title":"J Clin Oncol"},{"key":"592_CR22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.2003.04.069","volume":"21","author":"ACN Chevalier","year":"2003","unstructured":"Chevalier ACN, Fumoleau P et al (2003) Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) and\/or liposomal doxorubicin based chemotherapy (meeting abstracts). J Clin Oncol 21:463. (Abstract 1861)","journal-title":"J Clin Oncol"},{"issue":"2","key":"592_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/annonc\/mdf018","volume":"13","author":"V Dieras","year":"2002","unstructured":"Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C et al (2002) Multicentre phase II study of oxaliplatin as a single-agent in cisplatin\/carboplatin +\/\u2212 taxane-pretreated ovarian cancer patients. Ann Oncol 13(2):258\u2013266","journal-title":"Ann Oncol"},{"key":"592_CR24","unstructured":"Vermorken JBGM, Perren T et al (2001) Multicenter randomized phase II study of oxaliplatin (OXA) or topotecan (TOPO) in platinum-pretreated epithelial ovarian cancer (EOC) patients (pts) (meeting abstracts). J Clin Oncol 20. Abstract 847"},{"issue":"6","key":"592_CR25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","volume":"18","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P et al (2000) Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 18(6):1193\u20131202","journal-title":"J Clin Oncol"},{"issue":"10","key":"592_CR26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","volume":"7","author":"P Chollet","year":"1996","unstructured":"Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H et al (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7(10):1065\u20131070","journal-title":"Ann Oncol"},{"issue":"3","key":"592_CR27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/annonc\/mdj097","volume":"17","author":"P Viens","year":"2006","unstructured":"Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH et al (2006) A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17(3):429\u2013436","journal-title":"Ann Oncol"},{"issue":"2","key":"592_CR28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ygyno.2005.08.020","volume":"100","author":"MO Nicoletto","year":"2006","unstructured":"Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G et al (2006) Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol 100(2):318\u2013323","journal-title":"Gynecol Oncol"},{"issue":"2","key":"592_CR29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2004.04.020","volume":"94","author":"S Sundar","year":"2004","unstructured":"Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S et al (2004) Phase II trial of oxaliplatin and 5-fluorouracil\/leucovorin combination in epithelial ovarian carcinoma relapsing within 2\u00a0years of platinum-based therapy. Gynecol Oncol 94(2):502\u2013508","journal-title":"Gynecol Oncol"},{"issue":"5-6","key":"592_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000082921","volume":"67","author":"F Raspagliesi","year":"2004","unstructured":"Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67(5-6):376\u2013381","journal-title":"Oncology"},{"key":"592_CR31","unstructured":"Ferrandina GLM, Dagostino G et al (2004) Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer (meeting abstracts). J Clin Oncol 22. Abstract 5078"},{"key":"592_CR32","unstructured":"Arca RIJ, Lerzo G et al (2004) Gemcitabine (GEM) 1 oxaliplatin (OX) in patients (pts) with stage III\/IV ovarian cancer following 3 cycles of carboplatin (CB) 1 paclitaxel (PAC): preliminary report of a phase II study (meeting abstracts). J Clin Oncol 22. Abstract 5111"},{"key":"592_CR33","unstructured":"Germano DBD, Di Nota A et al (2004) Bi-weekly oxaliplatin (oxa) and gemcitabine (gem) in cisplatin pretreated patients with relapsed ovarian cancer (roc): preliminary data of a phase II trial (meeting abstracts). J Clin Oncol 22. Abstract 5104"},{"key":"592_CR34","first-page":"451","volume":"21","author":"NWB Dohollou","year":"2003","unstructured":"Dohollou NWB, Geay JF et al (2003) Gemcitabine (GE) and oxaliplatin (OX) in patients with recurrent advanced ovarian cancer in early progression (6\u00a0months) (AOCEP): a GINECO phase II trial (meeting abstracts). J Clin Oncol 21:451. (Abstract 1813)","journal-title":"J Clin Oncol"},{"issue":"9","key":"592_CR35","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdf219","volume":"13","author":"S Faivre","year":"2002","unstructured":"Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J et al (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13(9):1479\u20131489","journal-title":"Ann Oncol"},{"issue":"9","key":"592_CR36","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1023\/A:1008334215414","volume":"10","author":"S Faivre","year":"1999","unstructured":"Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM et al (1999) Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann Oncol 10(9):1125\u20131128","journal-title":"Ann Oncol"},{"issue":"9","key":"592_CR37","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0959-8049(97)00122-6","volume":"33","author":"P Soulie","year":"1997","unstructured":"Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M et al (1997) Oxaliplatin\/cisplatin (L-OHP\/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33(9):1400\u20131406","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"592_CR38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1525-1438.2006.00324.x","volume":"16","author":"MR Valerio","year":"2006","unstructured":"Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C et al (2006) A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. Int J Gynecol Cancer 16(Suppl 1):79\u201385","journal-title":"Int J Gynecol Cancer"},{"key":"592_CR39","unstructured":"Seliger GML, Buechele T et al (2002) Salvage chemotherapy with docetaxel, oxaliplatin and gemcitabine in platinum-pretreated advanced epithelial ovarian cancer: preliminary results of a phase II study (meeting abstracts). J Clin Oncol 20. Abstract 864"},{"key":"592_CR40","unstructured":"Osman ATA, Morgan B et al (2001) Phase II study of oxaliplatin (OXA) and 5-fluorouracil (5FU) in patients with relapsed ovarian cancer (ROC). J Clin Oncol 20. Abstract 2502"},{"issue":"6","key":"592_CR41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00000421-200012000-00007","volume":"23","author":"S Delaloge","year":"2000","unstructured":"Delaloge S, Laadem A, Taamma A, Chouaki N, Cvitkovic E, Pautier P et al (2000) Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced\/recurrent ovarian cancer. Am J Clin Oncol 23(6):569\u2013574","journal-title":"Am J Clin Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-008-0592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-008-0592-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-008-0592-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T13:44:54Z","timestamp":1559051094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-008-0592-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,14]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1007\/s00404-008-0592-9","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,14]]}}}